首页 > 最新文献

Circulation: Heart Failure最新文献

英文 中文
Infarct Size Reduction With Cyclosporine A in Circulatory Death Rat Hearts: Reducing Effective Ischemia Time With Therapy During Reperfusion. 用环孢素 A 减少循环死亡大鼠心脏的梗死面积:通过再灌注期间的治疗缩短有效缺血时间
IF 7.8 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-01 Epub Date: 2024-09-20 DOI: 10.1161/CIRCHEARTFAILURE.124.011846
Zachary Kiernan, Gina Labate, Qun Chen, Edward J Lesnefsky, Mohammed Quader
{"title":"Infarct Size Reduction With Cyclosporine A in Circulatory Death Rat Hearts: Reducing Effective Ischemia Time With Therapy During Reperfusion.","authors":"Zachary Kiernan, Gina Labate, Qun Chen, Edward J Lesnefsky, Mohammed Quader","doi":"10.1161/CIRCHEARTFAILURE.124.011846","DOIUrl":"10.1161/CIRCHEARTFAILURE.124.011846","url":null,"abstract":"","PeriodicalId":10196,"journal":{"name":"Circulation: Heart Failure","volume":" ","pages":"e011846"},"PeriodicalIF":7.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11479819/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142281230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Home-Time Is Good, but Feeling Well Is Better. Patient-Journey and Quality Home-Time as End Points in Heart Failure Trials and Registries. 在家时间固然好,但感觉良好更好。心力衰竭试验和登记中作为终点的 "患者旅程 "和 "高质量居家时间"。
IF 7.8 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-01 Epub Date: 2024-10-09 DOI: 10.1161/CIRCHEARTFAILURE.124.012263
John G F Cleland
{"title":"Home-Time Is Good, but Feeling Well Is Better. Patient-Journey and Quality Home-Time as End Points in Heart Failure Trials and Registries.","authors":"John G F Cleland","doi":"10.1161/CIRCHEARTFAILURE.124.012263","DOIUrl":"10.1161/CIRCHEARTFAILURE.124.012263","url":null,"abstract":"","PeriodicalId":10196,"journal":{"name":"Circulation: Heart Failure","volume":" ","pages":"e012263"},"PeriodicalIF":7.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142388499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sex Differences in Skeletal Muscle Pathology in Patients With Heart Failure and Reduced Ejection Fraction. 心力衰竭和射血分数降低患者骨骼肌病理学的性别差异
IF 7.8 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-01 Epub Date: 2024-10-09 DOI: 10.1161/CIRCHEARTFAILURE.123.011471
Nathanael Wood, Annabel Critchlow, Chew W Cheng, Sam Straw, Paul W Hendrickse, Marcelo G Pereira, Stephen B Wheatcroft, Stuart Egginton, Klaus K Witte, Lee D Roberts, T Scott Bowen

Background: Women with heart failure and reduced ejection fraction (HFrEF) have greater symptoms and a lower quality of life compared with men; however, the role of noncardiac mechanisms remains poorly resolved. We hypothesized that differences in skeletal muscle pathology between men and women with HFrEF may explain clinical heterogeneity.

Methods: Muscle biopsies from both men (n=22) and women (n=16) with moderate HFrEF (New York Heart Association classes I-III) and age- and sex-matched controls (n=18 and n=16, respectively) underwent transcriptomics (RNA-sequencing), myofiber structural imaging (histology), and molecular signaling analysis (gene/protein expression), with serum inflammatory profiles analyzed (enzyme-linked immunosorbent assay). Two-way ANOVA was conducted (interaction sex and condition).

Results: RNA-sequencing identified 5629 differentially expressed genes between men and women with HFrEF, with upregulated terms for catabolism and downregulated terms for mitochondria in men. mRNA expression confirmed an effect of sex (P<0.05) on proatrophic genes related to ubiquitin proteasome, autophagy, and myostatin systems (higher in all men versus all women), whereas proanabolic IGF1 expression was higher (P<0.05) in women with HFrEF only. Structurally, women compared with men with HFrEF showed a pro-oxidative phenotype, with smaller but higher numbers of type I fibers, alongside higher muscle capillarity (Pinteraction<0.05) and higher type I fiber areal density (Pinteraction<0.05). Differences in gene/protein expression of regulators of muscle phenotype were detected between sexes, including HIF1α, ESR1, VEGF (vascular endothelial growth factor), and PGC1α expression (P<0.05), and for upstream circulating factors, including VEGF, IL (interleukin)-6, and IL-8 (P<0.05).

Conclusions: Sex differences in muscle pathology in HFrEF exist, with men showing greater abnormalities compared with women related to the transcriptome, fiber phenotype, capillarity, and circulating factors. These preliminary data question whether muscle pathology is a primary mechanism contributing to greater symptoms in women with HFrEF and highlight the need for further investigation.

背景:与男性相比,患有射血分数降低型心力衰竭(HFrEF)的女性症状更重,生活质量更低;然而,非心脏机制的作用仍未得到很好的解决。我们假设,患有 HFrEF 的男性和女性在骨骼肌病理学方面的差异可能是临床异质性的原因:中度 HFrEF(纽约心脏协会 I-III 级)男性(n=22)和女性(n=16)以及年龄和性别匹配的对照组(分别为 n=18 和 n=16)的肌肉活检组织接受了转录组学(RNA 序列)、肌纤维结构成像(组织学)和分子信号转导分析(基因/蛋白表达),并对血清炎症概况进行了分析(酶联免疫吸附试验)。进行了双向方差分析(性别和条件交互作用):mRNA表达证实了性别的影响(PIGF1表达较高(PPinteractionPinteractionHIF1α、ESR1、VEGF(血管内皮生长因子)和PGC1α表达较高(PPConclusions:与女性相比,男性在转录组、纤维表型、毛细血管和循环因子方面表现出更大的异常。这些初步数据质疑了肌肉病理学是否是导致女性高频心衰患者出现更多症状的主要机制,并强调了进一步研究的必要性。
{"title":"Sex Differences in Skeletal Muscle Pathology in Patients With Heart Failure and Reduced Ejection Fraction.","authors":"Nathanael Wood, Annabel Critchlow, Chew W Cheng, Sam Straw, Paul W Hendrickse, Marcelo G Pereira, Stephen B Wheatcroft, Stuart Egginton, Klaus K Witte, Lee D Roberts, T Scott Bowen","doi":"10.1161/CIRCHEARTFAILURE.123.011471","DOIUrl":"10.1161/CIRCHEARTFAILURE.123.011471","url":null,"abstract":"<p><strong>Background: </strong>Women with heart failure and reduced ejection fraction (HFrEF) have greater symptoms and a lower quality of life compared with men; however, the role of noncardiac mechanisms remains poorly resolved. We hypothesized that differences in skeletal muscle pathology between men and women with HFrEF may explain clinical heterogeneity.</p><p><strong>Methods: </strong>Muscle biopsies from both men (n=22) and women (n=16) with moderate HFrEF (New York Heart Association classes I-III) and age- and sex-matched controls (n=18 and n=16, respectively) underwent transcriptomics (RNA-sequencing), myofiber structural imaging (histology), and molecular signaling analysis (gene/protein expression), with serum inflammatory profiles analyzed (enzyme-linked immunosorbent assay). Two-way ANOVA was conducted (interaction sex and condition).</p><p><strong>Results: </strong>RNA-sequencing identified 5629 differentially expressed genes between men and women with HFrEF, with upregulated terms for catabolism and downregulated terms for mitochondria in men. mRNA expression confirmed an effect of sex (<i>P</i><0.05) on proatrophic genes related to ubiquitin proteasome, autophagy, and myostatin systems (higher in all men versus all women), whereas proanabolic <i>IGF1</i> expression was higher (<i>P</i><0.05) in women with HFrEF only. Structurally, women compared with men with HFrEF showed a pro-oxidative phenotype, with smaller but higher numbers of type I fibers, alongside higher muscle capillarity (<i>P</i><sub>interaction</sub><0.05) and higher type I fiber areal density (<i>P</i><sub>interaction</sub><0.05). Differences in gene/protein expression of regulators of muscle phenotype were detected between sexes, including <i>HIF1α</i>, <i>ESR1</i>, <i>VEGF</i> (vascular endothelial growth factor), and PGC1α expression (<i>P</i><0.05), and for upstream circulating factors, including VEGF, IL (interleukin)-6, and IL-8 (<i>P</i><0.05).</p><p><strong>Conclusions: </strong>Sex differences in muscle pathology in HFrEF exist, with men showing greater abnormalities compared with women related to the transcriptome, fiber phenotype, capillarity, and circulating factors. These preliminary data question whether muscle pathology is a primary mechanism contributing to greater symptoms in women with HFrEF and highlight the need for further investigation.</p>","PeriodicalId":10196,"journal":{"name":"Circulation: Heart Failure","volume":" ","pages":"e011471"},"PeriodicalIF":7.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11472905/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142388501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to: Targeted Gene Deletion or Antagonism of the Prostaglandin E2 EP3 Receptor Protects Against Cardiac Injury Postmyocardial Infarction. 更正:靶向基因缺失或拮抗前列腺素 E2 EP3 受体可保护心肌梗死后的心脏损伤。
IF 7.8 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-01 Epub Date: 2024-10-15 DOI: 10.1161/HHF.0000000000000085
{"title":"Correction to: Targeted Gene Deletion or Antagonism of the Prostaglandin E2 EP3 Receptor Protects Against Cardiac Injury Postmyocardial Infarction.","authors":"","doi":"10.1161/HHF.0000000000000085","DOIUrl":"https://doi.org/10.1161/HHF.0000000000000085","url":null,"abstract":"","PeriodicalId":10196,"journal":{"name":"Circulation: Heart Failure","volume":"17 10","pages":"e000085"},"PeriodicalIF":7.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Myosin-Inhibitor Mavacamten Acutely Enhances Cardiomyocyte Diastolic Compliance in Heart Failure With Preserved Ejection Fraction. 肌球蛋白抑制剂马伐康坦可快速增强射血分数保留型心力衰竭患者心肌细胞的舒张顺应性
IF 7.8 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-01 Epub Date: 2024-09-06 DOI: 10.1161/CIRCHEARTFAILURE.124.011833
João Almeida-Coelho, André M Leite-Moreira, Vasco Sequeira, Nazha Hamdani, André P Lourenço, Inês Falcão-Pires, Adelino F Leite-Moreira
{"title":"Myosin-Inhibitor Mavacamten Acutely Enhances Cardiomyocyte Diastolic Compliance in Heart Failure With Preserved Ejection Fraction.","authors":"João Almeida-Coelho, André M Leite-Moreira, Vasco Sequeira, Nazha Hamdani, André P Lourenço, Inês Falcão-Pires, Adelino F Leite-Moreira","doi":"10.1161/CIRCHEARTFAILURE.124.011833","DOIUrl":"10.1161/CIRCHEARTFAILURE.124.011833","url":null,"abstract":"","PeriodicalId":10196,"journal":{"name":"Circulation: Heart Failure","volume":" ","pages":"e011833"},"PeriodicalIF":7.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142139434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Relationship Between Cardiac Structure and Function With Renal Function Trajectory and Outcomes in Patients With Heart Failure: Insights From the PARAGON-HF Trial. 心力衰竭患者的心脏结构和功能与肾功能轨迹和预后之间的关系:PARAGON-HF 试验的启示。
IF 7.8 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-01 Epub Date: 2024-08-30 DOI: 10.1161/CIRCHEARTFAILURE.124.011942
Henri Lu, Safia Chatur, Sahmin Lee, Riccardo M Inciardi, Martin Abanda, Finnian R Mc Causland, Arzu Kalayci, Kimia Karimi Taheri, Amil M Shah, Maja Cikes, Brian L Claggett, Narayana Prasad, Carolyn S P Lam, Eileen O'Meara, Xiaowen Wang, John J V McMurray, Marc A Pfeffer, Sheila M Hegde, Scott D Solomon, Hicham Skali

Background: Renal dysfunction is common and associated with a poor prognosis in patients with heart failure. However, the association of cardiac structure and function with decline in kidney function in this population is unknown. We aimed to assess the association between individual measures of cardiac structure and function with changes in renal function and renal outcomes in patients with heart failure with preserved ejection fraction.

Methods: Patients enrolled in the PARAGON-HF (Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor With Angiotensin-Receptor Blockers Global Outcomes in Heart Failure With Preserved Ejection Fraction) echocardiographic substudy were included. The association between each echocardiographic parameter (expressed in standardized units) and changes over time in estimated glomerular filtration rate was calculated with repeated-measures mixed-effect models. Multivariable Cox proportional hazards models were used to identify individual cardiac parameters associated with the composite renal outcome (≥50% decline in estimated glomerular filtration rate relative to baseline, development of end-stage renal disease, or death attributable to renal causes), after adjusting for covariates.

Results: Among 1097 patients (mean age 74±8 years and 53% women), over a median follow-up of 2.9 years, 28 composite renal events (0.9 per 100 person-years) occurred. Higher left ventricular (LV) mass index and higher E/average e' ratio were associated with significantly more profound annual decline in estimated glomerular filtration rate (for both, -0.4 [95% CI, -0.7 to -0.1] mL/min/1.73 m2/y per 1 higher SD). Higher LV mass index, LV end-diastolic volume index, right ventricular end-diastolic area, and a lower right ventricular fractional area change were each associated with a significantly higher risk for the composite renal outcome.

Conclusions: In the PARAGON-HF echocardiographic substudy, higher LV mass and filling pressures were independently associated with more profound kidney function decline, and higher LV mass and volume, as well as impaired right ventricular structure and function, were each associated with renal events. Assessing these parameters may help identify patients with heart failure with preserved ejection fraction at higher risk for adverse renal events and indicate potential therapeutic targets.

Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01920711.

背景:肾功能障碍在心力衰竭患者中很常见,而且与预后不良有关。然而,在这一人群中,心脏结构和功能与肾功能下降的关系尚不清楚。我们的目的是评估心脏结构和功能的各项指标与射血分数保留型心衰患者肾功能变化和肾脏预后之间的关系:方法:纳入 PARAGON-HF(血管紧张素受体-奈普利酶抑制剂与血管紧张素受体阻滞剂对射血分数保留型心力衰竭全球预后的前瞻性比较)超声心动图子研究的患者。采用重复测量混合效应模型计算了各超声心动图参数(以标准化单位表示)与估算肾小球滤过率随时间推移的变化之间的关系。在对协变量进行调整后,使用多变量考克斯比例危险模型确定与综合肾脏结果(估计肾小球滤过率相对于基线下降≥50%、发展为终末期肾病或因肾脏原因死亡)相关的单个心脏参数:在中位随访 2.9 年的 1097 名患者(平均年龄为 74±8岁,53% 为女性)中,共发生 28 起综合肾病事件(每 100 人年 0.9 起)。左心室质量指数越高,E/平均e'比值越高,估计肾小球滤过率的年下降幅度越大(两者均为-0.4 [95% CI, -0.7 to -0.1]毫升/分钟/1.73平方米/年,每高1 SD)。较高的左心室质量指数、左心室舒张末期容积指数、右心室舒张末期面积和较低的右心室折返面积变化均与较高的肾脏综合结局风险显著相关:在PARAGON-HF超声心动图子研究中,较高的左心室质量和充盈压与更严重的肾功能衰退独立相关,较高的左心室质量和容积以及受损的右心室结构和功能均与肾脏事件相关。评估这些参数有助于确定射血分数保留型心力衰竭患者发生不良肾脏事件的较高风险,并指出潜在的治疗目标:URL:https://www.clinicaltrials.gov;唯一标识符:NCT01920711。
{"title":"Relationship Between Cardiac Structure and Function With Renal Function Trajectory and Outcomes in Patients With Heart Failure: Insights From the PARAGON-HF Trial.","authors":"Henri Lu, Safia Chatur, Sahmin Lee, Riccardo M Inciardi, Martin Abanda, Finnian R Mc Causland, Arzu Kalayci, Kimia Karimi Taheri, Amil M Shah, Maja Cikes, Brian L Claggett, Narayana Prasad, Carolyn S P Lam, Eileen O'Meara, Xiaowen Wang, John J V McMurray, Marc A Pfeffer, Sheila M Hegde, Scott D Solomon, Hicham Skali","doi":"10.1161/CIRCHEARTFAILURE.124.011942","DOIUrl":"10.1161/CIRCHEARTFAILURE.124.011942","url":null,"abstract":"<p><strong>Background: </strong>Renal dysfunction is common and associated with a poor prognosis in patients with heart failure. However, the association of cardiac structure and function with decline in kidney function in this population is unknown. We aimed to assess the association between individual measures of cardiac structure and function with changes in renal function and renal outcomes in patients with heart failure with preserved ejection fraction.</p><p><strong>Methods: </strong>Patients enrolled in the PARAGON-HF (Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor With Angiotensin-Receptor Blockers Global Outcomes in Heart Failure With Preserved Ejection Fraction) echocardiographic substudy were included. The association between each echocardiographic parameter (expressed in standardized units) and changes over time in estimated glomerular filtration rate was calculated with repeated-measures mixed-effect models. Multivariable Cox proportional hazards models were used to identify individual cardiac parameters associated with the composite renal outcome (≥50% decline in estimated glomerular filtration rate relative to baseline, development of end-stage renal disease, or death attributable to renal causes), after adjusting for covariates.</p><p><strong>Results: </strong>Among 1097 patients (mean age 74±8 years and 53% women), over a median follow-up of 2.9 years, 28 composite renal events (0.9 per 100 person-years) occurred. Higher left ventricular (LV) mass index and higher E/average e' ratio were associated with significantly more profound annual decline in estimated glomerular filtration rate (for both, -0.4 [95% CI, -0.7 to -0.1] mL/min/1.73 m<sup>2</sup>/y per 1 higher SD). Higher LV mass index, LV end-diastolic volume index, right ventricular end-diastolic area, and a lower right ventricular fractional area change were each associated with a significantly higher risk for the composite renal outcome.</p><p><strong>Conclusions: </strong>In the PARAGON-HF echocardiographic substudy, higher LV mass and filling pressures were independently associated with more profound kidney function decline, and higher LV mass and volume, as well as impaired right ventricular structure and function, were each associated with renal events. Assessing these parameters may help identify patients with heart failure with preserved ejection fraction at higher risk for adverse renal events and indicate potential therapeutic targets.</p><p><strong>Registration: </strong>URL: https://www.clinicaltrials.gov; Unique identifier: NCT01920711.</p>","PeriodicalId":10196,"journal":{"name":"Circulation: Heart Failure","volume":" ","pages":"e011942"},"PeriodicalIF":7.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142104857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Single Arterial Access for VA-ECMO-Assisted Stenting of a Left Ventricular Assist Device Outflow Graft Obstruction in the Setting of an Oversewn Aortic Valve. 在主动脉瓣膜外缝合的情况下,为 VA-ECMO 辅助支架植入左心室辅助装置流出道阻塞的单动脉入路。
IF 7.8 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-01 Epub Date: 2024-10-09 DOI: 10.1161/CIRCHEARTFAILURE.124.011743
Navin K Kapur, Michael S Kiernan, Nicolas Ruiz, Haval Chweich
{"title":"Single Arterial Access for VA-ECMO-Assisted Stenting of a Left Ventricular Assist Device Outflow Graft Obstruction in the Setting of an Oversewn Aortic Valve.","authors":"Navin K Kapur, Michael S Kiernan, Nicolas Ruiz, Haval Chweich","doi":"10.1161/CIRCHEARTFAILURE.124.011743","DOIUrl":"10.1161/CIRCHEARTFAILURE.124.011743","url":null,"abstract":"","PeriodicalId":10196,"journal":{"name":"Circulation: Heart Failure","volume":" ","pages":"e011743"},"PeriodicalIF":7.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142388502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Equity in Heart Failure Care: A Get With the Guidelines Analysis of Between- and Within-Hospital Differences in Care by Sex, Race, Ethnicity, and Insurance. 心力衰竭护理的公平性:根据指南分析不同性别、种族、人种和保险在医院之间和医院内部的护理差异》(Get With the Guidelines Analysis of Between and Within-Hospital Differences in Care by Sex, Race, Ethnicity, and Insurance)。
IF 9.7 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-18 DOI: 10.1161/circheartfailure.123.011177
Alexander T Sandhu,Maria V Grau-Sepulveda,Celeste Witting,Rebecca L Tisdale,Jimmy Zheng,Fatima Rodriguez,Justin A Edward,Andrew P Ambrosy,Stephen J Greene,Brooke Alhanti,Gregg C Fonarow,Karen E Joynt Maddox,Paul A Heidenreich
BACKGROUNDDisparities in guideline-based quality measures likely contribute to differences in heart failure (HF) outcomes. We evaluated between- and within-hospital differences in the quality of care across sex, race, ethnicity, and insurance for patients hospitalized for HF.METHODSThis retrospective analysis included patients hospitalized for HF across 596 hospitals in the Get With the Guidelines-HF registry between 2016 and 2021. We evaluated performance across 7 measures stratified by patient sex, race, ethnicity, and insurance. We evaluated differences in performance with and without adjustment for the treating hospital. We also measured variation in hospital-specific disparities.RESULTSAmong 685 227 patients, the median patient age was 72 (interquartile range, 61-82) and 47.2% were women. Measure performance was significantly lower (worse) for women compared with men for all 7 measures before adjustment. For 4 of 7 measures, there were no significant sex-related differences after patient-level adjustment. For 20 of 25 other comparisons, racial and ethnic minorities and Medicaid/uninsured patients had similar or higher (better) adjusted measure performance compared with White and Medicare/privately insured patients, respectively. Angiotensin receptor neprilysin inhibitor measure performance was significantly lower for Asian, Hispanic, and Medicaid/uninsured patients, and cardiac resynchronization therapy implant/prescription was lower among women and Black patients after hospital adjustment, indicating within-hospital differences. There was hospital-level variation in these differences. For cardiac resynchronization therapy implantation/prescription, 278 hospitals (46.6%) had ≥2% lower implant/prescription for Black versus White patients compared with 109 hospitals (18.3%) with the same or higher cardiac resynchronization therapy implantation/prescription for Black patients.CONCLUSIONSHF quality measure performance was equitable for most measures. There were within-hospital differences in angiotensin receptor neprilysin inhibitor and cardiac resynchronization therapy implant/prescription for historically marginalized groups. The magnitude of hospital-specific disparities varied across hospitals.
背景基于指南的质量衡量标准的差异很可能导致心力衰竭(HF)结果的不同。我们评估了不同性别、种族、民族和保险的心力衰竭住院患者在医院间和医院内的医疗质量差异。方法这项回顾性分析纳入了 2016 年至 2021 年期间在《Get With the Guidelines-HF 》登记处的 596 家医院住院的心力衰竭患者。我们评估了按患者性别、种族、民族和保险分层的 7 项措施的绩效。我们评估了对治疗医院进行调整和未进行调整的绩效差异。结果在 685 227 名患者中,患者年龄中位数为 72 岁(四分位间范围为 61-82),47.2% 为女性。在调整前的所有 7 项测量中,女性的测量绩效明显低于男性(更差)。对于 7 项测量中的 4 项,在对患者水平进行调整后,与性别相关的差异并不明显。在其他 25 项比较中的 20 项比较中,少数种族和少数民族以及医疗补助/无保险患者与白人和医疗保险/私人保险患者相比,其调整后的测量结果分别相似或更高(更好)。经医院调整后,亚裔、西班牙裔和医疗补助/未参保患者的血管紧张素受体肾素抑制剂测量绩效明显较低,女性和黑人患者的心脏再同步化治疗植入/处方绩效较低,这表明医院内部存在差异。这些差异存在医院层面的差异。在心脏再同步化治疗植入/处方方面,278 家医院(46.6%)的黑人患者植入/处方比白人患者低≥2%,而 109 家医院(18.3%)的黑人患者心脏再同步化治疗植入/处方与白人患者相同或更高。历史上被边缘化的群体在血管紧张素受体肾素抑制剂和心脏再同步疗法植入/处方方面存在院内差异。各家医院的具体差异程度不尽相同。
{"title":"Equity in Heart Failure Care: A Get With the Guidelines Analysis of Between- and Within-Hospital Differences in Care by Sex, Race, Ethnicity, and Insurance.","authors":"Alexander T Sandhu,Maria V Grau-Sepulveda,Celeste Witting,Rebecca L Tisdale,Jimmy Zheng,Fatima Rodriguez,Justin A Edward,Andrew P Ambrosy,Stephen J Greene,Brooke Alhanti,Gregg C Fonarow,Karen E Joynt Maddox,Paul A Heidenreich","doi":"10.1161/circheartfailure.123.011177","DOIUrl":"https://doi.org/10.1161/circheartfailure.123.011177","url":null,"abstract":"BACKGROUNDDisparities in guideline-based quality measures likely contribute to differences in heart failure (HF) outcomes. We evaluated between- and within-hospital differences in the quality of care across sex, race, ethnicity, and insurance for patients hospitalized for HF.METHODSThis retrospective analysis included patients hospitalized for HF across 596 hospitals in the Get With the Guidelines-HF registry between 2016 and 2021. We evaluated performance across 7 measures stratified by patient sex, race, ethnicity, and insurance. We evaluated differences in performance with and without adjustment for the treating hospital. We also measured variation in hospital-specific disparities.RESULTSAmong 685 227 patients, the median patient age was 72 (interquartile range, 61-82) and 47.2% were women. Measure performance was significantly lower (worse) for women compared with men for all 7 measures before adjustment. For 4 of 7 measures, there were no significant sex-related differences after patient-level adjustment. For 20 of 25 other comparisons, racial and ethnic minorities and Medicaid/uninsured patients had similar or higher (better) adjusted measure performance compared with White and Medicare/privately insured patients, respectively. Angiotensin receptor neprilysin inhibitor measure performance was significantly lower for Asian, Hispanic, and Medicaid/uninsured patients, and cardiac resynchronization therapy implant/prescription was lower among women and Black patients after hospital adjustment, indicating within-hospital differences. There was hospital-level variation in these differences. For cardiac resynchronization therapy implantation/prescription, 278 hospitals (46.6%) had ≥2% lower implant/prescription for Black versus White patients compared with 109 hospitals (18.3%) with the same or higher cardiac resynchronization therapy implantation/prescription for Black patients.CONCLUSIONSHF quality measure performance was equitable for most measures. There were within-hospital differences in angiotensin receptor neprilysin inhibitor and cardiac resynchronization therapy implant/prescription for historically marginalized groups. The magnitude of hospital-specific disparities varied across hospitals.","PeriodicalId":10196,"journal":{"name":"Circulation: Heart Failure","volume":"48 1","pages":"e011177"},"PeriodicalIF":9.7,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142255579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Response by Kanaoka et al to Letter Regarding Article, "Changes in Cardiac Function Following Fulminant Myocarditis". Kanaoka 等人对有关 "暴发性心肌炎后心功能的变化 "一文的回信。
IF 7.8 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-01 Epub Date: 2024-08-20 DOI: 10.1161/CIRCHEARTFAILURE.124.012029
Koshiro Kanaoka, Kenji Onoue, Yoshihiko Saito
{"title":"Response by Kanaoka et al to Letter Regarding Article, \"Changes in Cardiac Function Following Fulminant Myocarditis\".","authors":"Koshiro Kanaoka, Kenji Onoue, Yoshihiko Saito","doi":"10.1161/CIRCHEARTFAILURE.124.012029","DOIUrl":"10.1161/CIRCHEARTFAILURE.124.012029","url":null,"abstract":"","PeriodicalId":10196,"journal":{"name":"Circulation: Heart Failure","volume":" ","pages":"e012029"},"PeriodicalIF":7.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142003734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reflections on the Win Ratio With Time-to-Event Outcomes. 对时间-事件结果胜率的思考。
IF 7.8 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-01 Epub Date: 2024-08-28 DOI: 10.1161/CIRCHEARTFAILURE.124.012186
Janet Wittes
{"title":"Reflections on the Win Ratio With Time-to-Event Outcomes.","authors":"Janet Wittes","doi":"10.1161/CIRCHEARTFAILURE.124.012186","DOIUrl":"10.1161/CIRCHEARTFAILURE.124.012186","url":null,"abstract":"","PeriodicalId":10196,"journal":{"name":"Circulation: Heart Failure","volume":" ","pages":"e012186"},"PeriodicalIF":7.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142079350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Circulation: Heart Failure
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1